Loading...
•
Dec 31, 2024
Incyte Q4 2024 Earnings Report
Key Takeaways
Incyte reported strong fourth-quarter 2024 results, with total revenues increasing 16% year-over-year to $1.18 billion. Growth was primarily driven by Jakafi ($773M, +11% YoY) and Opzelura ($162M, +48% YoY). GAAP net income remained stable at $201M, while non-GAAP net income rose 18% to $281M. GAAP diluted EPS was $1.02, and non-GAAP diluted EPS was $1.43.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Incyte expects continued revenue growth in 2025, driven by increased Jakafi and Opzelura sales, alongside pipeline advancements.
Positive Outlook
- Jakafi revenue expected to grow to $2.925B - $2.975B in 2025
- Opzelura revenue guidance increased to $630M - $670M
- Four new product launches planned in 2025
- Expansion of Opzelura in pediatric atopic dermatitis
- R&D milestones including pivotal study readouts and Phase 3 initiations
Challenges Ahead
- Increased R&D expenses impacting profitability
- Higher SG&A costs due to commercial expansion
- Potential competition in the JAK inhibitor market
- Regulatory uncertainties for new product approvals
- Foreign exchange fluctuations affecting revenues
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...